Low-Level Laser Therapy (LLLT) for Neuropathy

Low-level laser therapy (LLLT), also called photobiomodulation (PBM), uses specific wavelengths of red and near-infrared light to penetrate tissue and stimulate cellular energy production at the mitochondrial level. Unlike surgical lasers, LLLT uses non-thermal energy levels that do not heat or damage tissue — instead, the light triggers biochemical changes that may reduce inflammation, increase local circulation, and support nerve fiber repair. A growing body of clinical evidence suggests that LLLT may offer meaningful pain relief for several types of peripheral neuropathy, including diabetic, chemotherapy-induced, and idiopathic neuropathy. As with all neuropathy treatments, results vary between individuals, and LLLT is best used as part of a comprehensive management plan discussed with your healthcare provider.

Evidence: Moderate — multiple randomized controlled trials show statistically significant pain reduction, particularly in diabetic peripheral neuropathy. A 2017 Cochrane-adjacent systematic review found beneficial effects in several neuropathy subtypes. Evidence is stronger for clinical-grade devices than consumer home devices.

How It Works

LLLT works primarily by stimulating cytochrome c oxidase, an enzyme in the mitochondrial electron transport chain that plays a central role in cellular energy (ATP) production. When specific wavelengths — typically 630 to 1000 nanometers in the red and near-infrared spectrum — are absorbed by this enzyme, it triggers a cascade of downstream effects: increased nitric oxide release (improving local blood flow), reduced oxidative stress, and activation of growth factors that support nerve repair and regeneration. In peripheral nerves, this may mean faster remyelination of damaged fibers and improved axonal transport.

For neuropathy specifically, research suggests that LLLT may also reduce the activity of pain-signaling neurons and decrease local inflammation in the nerve microenvironment. The depth of light penetration varies by wavelength and power density — near-infrared wavelengths around 800 to 900 nm penetrate more deeply into tissue than red wavelengths around 660 nm, making them more relevant for deep nerve structures in the foot. Clinical devices and high-quality home devices use precise wavelengths and dosing parameters to optimize these effects.

What the Research Shows

Multiple randomized controlled trials have investigated LLLT for diabetic peripheral neuropathy, with several showing statistically significant reductions in pain scores, improvements in nerve conduction velocity, and increased intraepidermal nerve fiber density compared to sham treatment. A notable 2015 RCT published in Photomedicine and Laser Surgery found that 12 sessions of LLLT significantly reduced neuropathic pain and improved nerve function in diabetic neuropathy patients versus controls.

For chemotherapy-induced peripheral neuropathy, smaller studies and case series have shown promising results, and scrambler therapy trials have sometimes incorporated photobiomodulation as a comparator arm. Evidence in idiopathic neuropathy is more limited but supportive. Research using home-use infrared devices (such as the Anodyne system) demonstrated improved sensation and balance in patients with diabetic neuropathy in early studies, though the device is no longer commercially marketed.

Important caveats: study quality varies, sample sizes tend to be small, and optimal dosing parameters (wavelength, power density, session duration, frequency) have not been standardized. Patients should interpret marketing claims critically and discuss the evidence with their treating physician.

What to Expect at a Clinic

Clinical LLLT for neuropathy is typically administered using a handheld or pad-based device that delivers light to the affected area — most commonly the feet, ankles, and lower legs. A typical session lasts 10 to 20 minutes and is completely painless. You may feel mild warmth from some devices, but there is no heat sensation from properly calibrated low-level laser or LED systems.

Most clinic-based protocols involve two to three sessions per week for four to six weeks as an initial course, followed by reassessment. Many patients begin noticing changes in sensation or reduction in pain symptoms by weeks two to four, though some require the full course before experiencing measurable benefit. Some practitioners combine LLLT with TENS, manual therapy, or other modalities in the same session.

When selecting a clinic, look for practitioners who can explain the specific wavelengths and power density parameters of their device, have experience treating neuropathy specifically (not just musculoskeletal pain), and take a comprehensive approach that includes medical oversight. Ask whether the clinic coordinates with your neurologist or primary care provider.

Home Devices vs. Clinical Treatment

A growing number of consumer-grade red light therapy and near-infrared devices are marketed for home use, ranging from handheld wands to full foot pads and larger panel systems. Home devices offer convenience and lower per-treatment cost over time, but generally operate at lower power densities than clinical devices — which may mean more treatment time is needed to achieve comparable photon doses to the target tissue.

For home devices, look for products that specify the wavelengths used (630–670 nm red and 800–850 nm near-infrared are most studied), the power density (mW/cm²), and the treatment area. Devices designed specifically for foot neuropathy — such as wrap-around pads or insoles with embedded LEDs — may deliver light more effectively to the plantar surface than generic panel devices. Expect to invest $300 to $1,500 for a quality home device with meaningful power output.

Home devices are not a substitute for professional evaluation and should not delay appropriate medical diagnosis and treatment. They are best used as a complement to medical care, ideally with your doctor’s knowledge. Always avoid shining any laser or bright LED device into the eyes, and follow manufacturer protocols for session duration and frequency.

Possible Side Effects

• mild temporary warmth during treatment with some devices
• brief temporary increase in pain or tingling immediately post-session in some patients
• skin redness that resolves within hours
• rare: eye injury if device is pointed at eyes without protective eyewear

Frequently Asked Questions

How many LLLT sessions does it take to see results for neuropathy?

Most clinical studies use 10 to 20 sessions over four to six weeks. Many patients report initial changes in sensation or pain by sessions four to eight, though the full benefit may not be apparent until after the complete treatment course. A subset of patients see little or no response — response rates in published trials typically range from 60 to 80 percent.

Is low-level laser therapy covered by Medicare or insurance?

Currently, LLLT for neuropathy is not covered by Medicare and is not covered by most commercial insurance plans, as it is classified as investigational for this indication by many payers. This means patients typically pay out of pocket. Costs vary widely by clinic — ask for a full quote before beginning treatment.

Can LLLT be used alongside my current neuropathy medications?

LLLT is generally considered safe to use alongside standard neuropathy medications such as gabapentin, pregabalin, and duloxetine. It works through a different mechanism than these medications, so there is no known pharmacological interaction. Always inform your prescribing physician about any additional treatments you are pursuing.

Is LLLT the same as infrared light therapy?

They overlap significantly. Low-level laser therapy originally used coherent laser light, while infrared light therapy devices typically use LEDs (non-coherent). Modern research suggests the coherence of laser light matters less than wavelength and power dose — making high-quality LED devices therapeutically similar to lasers at equivalent doses. ‘Photobiomodulation’ is the more current umbrella term for both.